Health TrialsbyHealthPanel

Development of a FibroScan Liver Examination Using a Single Probe

ConditionLiver Diseases
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorEchosens

About this trial

This is an exploratory, international, prospective, interventional, multicenter clinical investigation that will take place in 1 Hong Kong site and 3 French sites and 309 adults patients will be included. The study objective is to assess the LSM reproducibility between the FibroScan examination performed with the Single Probe (SP) and the FibroScan examination performed with the reference probes (M and XL).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adult patients (≥ 18 years of age).

Patient followed with a chronic liver disease.

Adult patient able to give his written consent.

For European sites: patient affiliated to the healthcare system.

Disqualifiers

Vulnerable patients.

Patients with ascites.

Patients with heart failure.

Patients with acute hepatitis.

Trial design

Design model

Single group

Treatments tested in this trial

  • Research FibroScan

    Device

    \*Patients #1 to #50: Exam 1: Examination with Research FibroScan and single probe #1 (SP1). Exam 2: Examination with Research FibroScan and single probe #2 (SP2). Exam 3: Examination with Research FibroScan and single probe #3 (SP3). Exam 4: Examination with the Reference FibroScan at the same measurement point. The examination must start alternatively with the FS exam using the SP1 probe, the SP2 probe or the SP3 probe to avoid potential bias. The standard examination must be always done at the end, after the first 3 exploratory exams. \*Patients #51 to #309: Exam 1: Examination with the Research FibroScan. Exam 2: Examination with the Reference FibroScan at the same measurement point. The examination must start alternatively with the Research FibroScan and the Reference FibroScan to avoid potential bias.

Treatment groups

309 Participants
are divided into 1 treatment group
Group A: All patientsExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Difference between LSM by guided-VCTE performed with the single probe and LSM by guided-VCTE performed with the reference probes (M and XL).

This outcome assesses the difference between the values of LSM obtained with the single probe and the reference probes (M and XL) when performed in the same patients.

Time frame
At Day 0

Secondary outcomes

1

Difference between CAP performed with single probe and CAP performed with the reference probes (M and XL).

This outcome assesses the difference between the CAP measurements obtained with the single probe and the reference probes (M and XL) when performed in the same patients.

Time frame
At Day 0
2

Difference of patient percentage having a successful examination between the FibroScan (guided-VCTE) examination performed with the single probe and the FibroScan (guided-VCTE) examination performed with the reference FibroScan probes (M and XL probes).

This outcome compare the applicability of FibroScan examinations performed with the single probe compared with the reference probes (M and XL).

Time frame
At Day 0
3

Difference between the values reported by the patient on the comfort scale after a FibroScan (guided-VCTE) examination performed with the single probe and after a FibroScan examination (guided-VCTE) performed with the reference probes (M and XL).

This outcome evaluates the difference in patient-reported comfort following FibroScan examinations performed with the single probe versus the reference probes (M and XL), as reported by patients after undergoing the examinations under similar conditions. A comfort scale from 0 to 10 will be given to the patients, where 10 represents the most confortable and 0 the more incomfortable.

Time frame
At Day 0

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Echosens

Lead sponsor

Novotech CRO

Collaborator

Source ClinicalTrials.gov
Apply now